DK1715887T3 - N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf - Google Patents
N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen derafInfo
- Publication number
- DK1715887T3 DK1715887T3 DK05702331T DK05702331T DK1715887T3 DK 1715887 T3 DK1715887 T3 DK 1715887T3 DK 05702331 T DK05702331 T DK 05702331T DK 05702331 T DK05702331 T DK 05702331T DK 1715887 T3 DK1715887 T3 DK 1715887T3
- Authority
- DK
- Denmark
- Prior art keywords
- growth hormone
- human growth
- preparation
- methods
- hgh
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 5
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 5
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 5
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/771,895 US20040142870A1 (en) | 2002-11-20 | 2004-02-04 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
PCT/IB2005/000171 WO2005079838A1 (en) | 2004-02-04 | 2005-01-24 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1715887T3 true DK1715887T3 (da) | 2007-09-17 |
Family
ID=34886516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05702331T DK1715887T3 (da) | 2004-02-04 | 2005-01-24 | N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf |
Country Status (21)
Country | Link |
---|---|
US (1) | US20040142870A1 (da) |
EP (2) | EP1715887B1 (da) |
JP (3) | JP2007520544A (da) |
KR (2) | KR20070039623A (da) |
CN (1) | CN1929857A (da) |
AT (1) | ATE365047T1 (da) |
AU (1) | AU2005215250A1 (da) |
BR (1) | BRPI0507427A (da) |
CA (1) | CA2555772A1 (da) |
CY (1) | CY1106723T1 (da) |
DE (1) | DE602005001445T2 (da) |
DK (1) | DK1715887T3 (da) |
ES (1) | ES2286787T3 (da) |
IL (1) | IL176998A0 (da) |
NO (1) | NO20063926L (da) |
PL (1) | PL1715887T3 (da) |
PT (1) | PT1715887E (da) |
RU (1) | RU2006128293A (da) |
TW (2) | TW200529868A (da) |
WO (1) | WO2005079838A1 (da) |
ZA (2) | ZA200706349B (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
RS20050202A (en) | 2002-09-09 | 2007-08-03 | Nektar Therapeuticals Al.Corporation, | Water-soluble polymer alkanals |
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
JP2006519170A (ja) * | 2002-12-26 | 2006-08-24 | マウンテン ビュー ファーマシューティカルズ,インコーポレイテッド | サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体 |
GEP20084486B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
JP2008510706A (ja) * | 2004-08-18 | 2008-04-10 | エリクシアー ファーマシューティカルズ, インコーポレイテッド | 成長ホルモン分泌促進物質 |
US20090269843A1 (en) * | 2004-08-20 | 2009-10-29 | Novo Nordisk A/S | Hemopexin fusion proteins |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
US20090105134A1 (en) * | 2005-02-10 | 2009-04-23 | Novo Nordisk A/S | C-Terminally Pegylated Growth Hormones |
US20060233740A1 (en) * | 2005-03-23 | 2006-10-19 | Bossard Mary J | Conjugates of an hGH moiety and a polymer |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
CA2627939A1 (en) * | 2005-12-15 | 2007-06-21 | Laboratoires Serono S.A. | New chemokine antagonists |
WO2007139997A2 (en) * | 2006-05-26 | 2007-12-06 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Methods for site-specific pegylation |
EP2272875B1 (en) * | 2008-04-03 | 2014-01-15 | Biosteed Gene Expression Tech. CO., LTD. | Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof |
CN102989001B (zh) | 2008-04-29 | 2014-12-03 | 阿森迪斯药物生长障碍股份有限公司 | Peg化的重组人生长激素化合物 |
EP2113256A1 (en) | 2008-04-29 | 2009-11-04 | Ascendis Pharma AS | PEGylated rhGH compounds |
TWI421093B (zh) * | 2008-07-31 | 2014-01-01 | Pharmaessentia Corp | 胜肽-聚合物綴合物 |
LT2393828T (lt) | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2011018515A1 (en) * | 2009-08-14 | 2011-02-17 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
RU2012129674A (ru) | 2009-12-15 | 2014-01-27 | Аспендис Фарма Ас | Композиция гормона роста |
CN102453089B (zh) * | 2010-10-25 | 2014-06-04 | 北京凯因科技股份有限公司 | 重组集成干扰素变异体聚乙二醇偶联物的制备和应用 |
KR102148910B1 (ko) * | 2011-12-09 | 2020-08-28 | 메타볼릭 파마슈티칼즈 피티와이 엘티디 | 성장 호르몬 단편들의 사용 |
CN102964588A (zh) * | 2012-11-09 | 2013-03-13 | 河南工业大学 | 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用 |
HUE056849T2 (hu) | 2014-11-21 | 2022-03-28 | Ascendis Pharma Endocrinology Div A/S | Hosszú hatástartalmú növekedési hormon adagolási formák |
KR101599415B1 (ko) | 2015-05-29 | 2016-03-03 | (주)신명이앤씨 | 건축물 층간 바닥 전기 케이블 보호관 |
CN114539384B (zh) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008505B1 (ru) * | 2001-11-20 | 2007-06-29 | Фармация Корпорейшн | Конъюгаты химически модифицированного гормона роста человека |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
-
2004
- 2004-02-04 US US10/771,895 patent/US20040142870A1/en not_active Abandoned
-
2005
- 2005-01-24 DE DE602005001445T patent/DE602005001445T2/de not_active Expired - Fee Related
- 2005-01-24 CN CNA2005800073938A patent/CN1929857A/zh active Pending
- 2005-01-24 EP EP05702331A patent/EP1715887B1/en active Active
- 2005-01-24 WO PCT/IB2005/000171 patent/WO2005079838A1/en active IP Right Grant
- 2005-01-24 PT PT05702331T patent/PT1715887E/pt unknown
- 2005-01-24 ZA ZA200706349A patent/ZA200706349B/xx unknown
- 2005-01-24 DK DK05702331T patent/DK1715887T3/da active
- 2005-01-24 AT AT05702331T patent/ATE365047T1/de not_active IP Right Cessation
- 2005-01-24 PL PL05702331T patent/PL1715887T3/pl unknown
- 2005-01-24 EP EP07110559A patent/EP1915999A1/en not_active Withdrawn
- 2005-01-24 RU RU2006128293/14A patent/RU2006128293A/ru not_active Application Discontinuation
- 2005-01-24 AU AU2005215250A patent/AU2005215250A1/en not_active Abandoned
- 2005-01-24 KR KR1020077007102A patent/KR20070039623A/ko not_active Application Discontinuation
- 2005-01-24 CA CA002555772A patent/CA2555772A1/en not_active Abandoned
- 2005-01-24 ES ES05702331T patent/ES2286787T3/es active Active
- 2005-01-24 BR BRPI0507427-4A patent/BRPI0507427A/pt not_active IP Right Cessation
- 2005-01-24 KR KR1020067015733A patent/KR100776862B1/ko not_active IP Right Cessation
- 2005-01-24 JP JP2006551943A patent/JP2007520544A/ja active Pending
- 2005-02-03 TW TW094103308A patent/TW200529868A/zh unknown
- 2005-02-03 TW TW096134157A patent/TW200812610A/zh unknown
-
2006
- 2006-07-20 IL IL176998A patent/IL176998A0/en unknown
- 2006-08-01 ZA ZA200606375A patent/ZA200606375B/xx unknown
- 2006-09-01 NO NO20063926A patent/NO20063926L/no not_active Application Discontinuation
-
2007
- 2007-07-12 CY CY20071100928T patent/CY1106723T1/el unknown
- 2007-08-15 JP JP2007211682A patent/JP2008037872A/ja not_active Withdrawn
- 2007-08-15 JP JP2007211676A patent/JP2008001713A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ZA200706349B (en) | 2008-06-25 |
EP1915999A1 (en) | 2008-04-30 |
ES2286787T3 (es) | 2007-12-01 |
TW200529868A (en) | 2005-09-16 |
TW200812610A (en) | 2008-03-16 |
NO20063926L (no) | 2006-10-30 |
JP2008037872A (ja) | 2008-02-21 |
JP2008001713A (ja) | 2008-01-10 |
DE602005001445T2 (de) | 2008-02-14 |
KR20060120240A (ko) | 2006-11-24 |
CN1929857A (zh) | 2007-03-14 |
EP1715887A1 (en) | 2006-11-02 |
KR20070039623A (ko) | 2007-04-12 |
AU2005215250A1 (en) | 2005-09-01 |
KR100776862B1 (ko) | 2007-11-28 |
BRPI0507427A (pt) | 2007-06-26 |
PL1715887T3 (pl) | 2007-12-31 |
WO2005079838A1 (en) | 2005-09-01 |
ZA200606375B (en) | 2007-11-28 |
PT1715887E (pt) | 2007-08-29 |
US20040142870A1 (en) | 2004-07-22 |
ATE365047T1 (de) | 2007-07-15 |
IL176998A0 (en) | 2006-12-10 |
EP1715887B1 (en) | 2007-06-20 |
RU2006128293A (ru) | 2008-02-10 |
CY1106723T1 (el) | 2012-05-23 |
DE602005001445D1 (de) | 2007-08-02 |
CA2555772A1 (en) | 2005-09-01 |
JP2007520544A (ja) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1715887T3 (da) | N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf | |
MX344559B (es) | Compuestos de hormona de crecimiento humana recombinante unidos al peg. | |
AP2004003050A0 (en) | Chemically modified human growth hormone conjugates | |
ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
EP2298811B8 (en) | Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors | |
DE60323090D1 (de) | 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten | |
ATE459357T1 (de) | Kombinationen zur behandlung von multiplem myelom | |
IS8432A (is) | Mótefni sem bindast viðtaka hvítfrumuboða-4 | |
TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
AR063150A1 (es) | Formulaciones estables | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
DK1992695T3 (da) | Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf | |
EP2107071A3 (en) | Anti-EpCAM immunoglobulins | |
WO2003079993A3 (en) | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION | |
EP1544214A4 (en) | Non-neutralizing anti-aPC antibodies | |
EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
HUP0402334A2 (hu) | Módosított humán növekedési hormon | |
MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
AU2003240790A1 (en) | Antibody peg positional isomers, compositions comprising same, and use thereof | |
DK1196188T3 (da) | VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser | |
SE0100873D0 (sv) | Method of treatment | |
ITMI20041871A1 (it) | Uso di santoreggia satureja montana o dei suoi estratti per la preparazione di medicamenti per il trattamento dell'eiaculazione precoce | |
ATE526983T1 (de) | Verwendung von peptiden aus dem wachstumsfaktors amp-18 zur behandlung von stomatitis |